GUSTO V: Combination drug treatment of acute myocardial infarction

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 7, 2002, Pages 554-560

  Askari, Arman T ^a   Lincoff, A Michael ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; RETEPLASE; STREPTOKINASE; TENECTOPLASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036066208     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.7.554     Document Type: Article

References (32)

1. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
3. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
4. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
5. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
6. Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Comparison of Thrombolytics (INJECT) trial
7. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
8. Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival
9. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators J. Am. Coll. Cardiol
10. A comparison of reteplase with alteplase for acute myocardial infarction
11. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators
12. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction
13. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade
14. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
15. Time to treatment influences the impact of ST-segment resolution on one-year prognosis: Insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial
16. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
17. Early reinfarction after fibrinolysis: Experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to coronary arteries (GUSTO III) trials
18. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (Thrombolysis in Myocardial Infarction) 14
19. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction
20. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
21. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: A meta-analysis
22. Profile and prevalence of aspirin resistance in patients with cardiovascular disease
23. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
24. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators
25. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
26. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial
27. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial
28. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa of Ischemic Complication
29. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators
30. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
31. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial
32. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients